Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
:MTNB
Total Valuation
Matinas BioPharma has a market cap or net worth of $4.65M. The enterprise value is $482.42K.
Market Cap$4.65M
Enterprise Value$482.42K
Share Statistics
Matinas BioPharma has 6,406,191 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,406,191
Owned by Insiders13.11%
Owned by Institutions0.77%
Financial Efficiency
Matinas BioPharma’s return on equity (ROE) is -3.20 and return on invested capital (ROIC) is -187.71%.
Return on Equity (ROE)-3.20
Return on Assets (ROA)-1.92
Return on Invested Capital (ROIC)-187.71%
Return on Capital Employed (ROCE)-2.02
Revenue Per Employee0.00
Profits Per Employee-8.08M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Matinas BioPharma is ―. Matinas BioPharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.33
Price to Fair Value0.33
Price to FCF-0.16
Price to Operating Cash Flow-0.72
PEG Ratio0.02
Income Statement
In the last 12 months, Matinas BioPharma had revenue of 0.00 and earned -24.25M in profits. Earnings per share was -4.98.
Revenue0.00
Gross Profit0.00
Operating Income-24.59M
Pretax Income-24.33M
Net Income-24.25M
EBITDA-19.19M
Earnings Per Share (EPS)-4.98
Cash Flow
In the last 12 months, operating cash flow was -9.01M and capital expenditures 0.00, giving a free cash flow of -9.01M billion.
Operating Cash Flow-9.01M
Free Cash Flow-9.01M
Free Cash Flow per Share-1.41
Dividends & Yields
Matinas BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.99
52-Week Price Change33.33%
50-Day Moving Average1.15
200-Day Moving Average1.09
Relative Strength Index (RSI)35.60
Average Volume (3m)52.28K
Important Dates
Matinas BioPharma upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateAug 19, 2025
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Matinas BioPharma as a current ratio of 3.01, with Debt / Equity ratio of 36.13%
Current Ratio3.01
Quick Ratio3.01
Debt to Market Cap0.00
Net Debt to EBITDA0.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Matinas BioPharma has paid -80.00K in taxes.
Income Tax-80.00K
Effective Tax Rate0.00
Enterprise Valuation
Matinas BioPharma EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.12.
EV to Sales0.00
EV to EBITDA0.08
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.12
Balance Sheet
Matinas BioPharma has $5.43M in cash and marketable securities with $2.33M in debt, giving a net cash position of $3.10M billion.
Cash & Marketable Securities$5.43M
Total Debt$2.33M
Net Cash$3.10M
Net Cash Per Share$0.48
Tangible Book Value Per Share$1.10
Margins
Gross margin is 23.80%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin23.80%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Matinas BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast25.19%